Quantum Biopharma adds April release to registration

Quantum Biopharma Ltd. updates a prior Form 6-K so its April 1, 2026 press release is formally incorporated into its Form F-3 registration statement.

Rhea-AI Filing Summary

Quantum Biopharma Ltd. (QNTM) filed an amended Form 6-K to change the treatment of a prior disclosure. The amendment specifies that Exhibit 99.1 from the Form 6-K furnished on April 1, 2026 is now incorporated by reference into the company’s Registration Statement on Form F-3 (File No. 333-276264).

The amendment makes no other changes to the earlier report and is a procedural step to ensure the April 1, 2026 press release forms part of the Form F-3 registration record, unless later superseded by subsequent filings.

Key Terms

Form 6-K, foreign private issuer, Form F-3, incorporated by reference

4 terms

Form 6-K regulatory

"This Amendment No. 1 to the report on Form 6-K originally furnished"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Form F-3 regulatory

"into the Registrant’s Registration Statement on Form F-3 (File No. 333-276264)"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

incorporated by reference regulatory

"Exhibit 99.1 included with this Amendment No. 1 is hereby incorporated by reference"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Quantum Biopharma Ltd. (QNTM) change in this Form 6-K/A?

The amendment states that Exhibit 99.1 from the Form 6-K furnished on April 1, 2026 is incorporated by reference into Quantum Biopharma’s Form F-3 Registration Statement (File No. 333-276264). No other changes to the prior report are made.

Which exhibit is incorporated into Quantum Biopharma (QNTM)’s Form F-3?

The filing incorporates Exhibit 99.1, described as the press release dated April 1, 2026, into Quantum Biopharma’s Registration Statement on Form F-3, to the extent it is not later superseded by subsequent documents.

Does this Quantum Biopharma (QNTM) Form 6-K/A change any financial or operational information?

No. The amendment states that, except as set forth in incorporating Exhibit 99.1 into the Form F-3, there are no other changes to the original April 1, 2026 Form 6-K report.

Who signed this Form 6-K/A for Quantum Biopharma Ltd. (QNTM)?

The amendment was signed on behalf of Quantum Biopharma Ltd. by Donal Carroll, identified as Chief Financial Officer, dated September 8, 2026.

What type of document is Exhibit 99.1 for Quantum Biopharma (QNTM)?

Exhibit 99.1 is identified as a Press Release dated April 1, 2026, previously furnished as part of the original Form 6-K with Accession No. -26-002144.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 12:39 PM EDT Accepted by SEC EDGAR 09/08/2026 - 12:39 PM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K/A

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Commission File Number:  001-39152

QUANTUM BIOPHARMA LTD.

(Registrant)

1 Adelaide Street East, Suite 801

Toronto, Ontario M5C 2V9

(Address of Principal Executive Offices) 

Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

EXPLANATORY NOTE

This Amendment No. 1 (this “Amendment No. 1”) to the report on Form 6-K originally furnished with the U.S. Securities and Exchange Commission on April 1, 2026, Accession Number 0001171843-26-002144 (the “Initial Report”), is being furnished solely to incorporate Exhibit 99.1 filed as part of the Initial Report into the Registrant’s Registration Statement on Form F-3 (File No. 333-276264). Except as set forth herein, there are no other changes to the Initial Report.

1

DOCUMENTS INCORPORATED BY REFERENCE

Exhibit 99.1 included with this Amendment No. 1 is hereby incorporated by reference into the Registrant’s Registration Statement on Form F-3 (File No. 333-276264) and shall be deemed to be a part thereof from the date on which the Initial Report was furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	QUANTUM BIOPHARMA LTD.
	(Registrant)
Date: September 8, 2026	By	/s/ Donal Carroll
		Donal Carroll
		Chief Financial Officer

3

EXHIBIT INDEX

Exhibit		Description of Exhibit
99.1		Press Release dated April 1, 2026 (incorporated by reference to Exhibit 99.1 to the Form 6-K furnished on April 1, 2026, Accession No. 0001171843-26-002144)

4